Idiopathic pulmonary fibrosis

The Lancet

Volumn 389, Issue 10082, 2017, Pages 1941-1952

  Richeldi, Luca ^a,b   Collard, Harold R ^c   Jones, Mark G ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NINTEDANIB; PIRFENIDONE; PLACEBO;

ANTIMICROBIAL THERAPY; CLINICAL FEATURE; ENVIRONMENTAL EXPOSURE; FIBROGENESIS; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; GENETIC SCREENING; HEREDITY; HUMAN; LUNG FIBROSIS; LUNG TRANSPLANTATION; MICROBIOME; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; REVIEW;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS;

EID: 85016515883     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30866-8     Document Type: Review

References (140)

1. International Agency for Research on Cancer. Cancer incidence in five continents. http://www.iarc.fr/en/publications/pdfs-online/epi/sp164/CI5volX_Full.pdf, 2014 (accessed Oct 1, 2016).
2. Hutchinson, J, Fogarty, A, Hubbard, R, McKeever, T, Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Resp J 46 (2015), 795–806.
3. Hopkins, RB, Fell, C, Dion, G, Kolb, M, Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J 48 (2016), 187–195.
4. Raghu, G, Collard, HR, Egan, JJ, et al., for the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis Study Group. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
5. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161 (2000), 646–664.
6. Raghu, G, Weycker, D, Edelsberg, J, Bradford, WZ, Oster, G, Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174 (2006), 810–816.
7. Ley, B, Collard, HR, King, TE, Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183 (2011), 431–440.
8. Selman, M, King, TE, Pardo, A for the American Thoracic Society Study Group European Respiratory Society Study Group, American College of Chest Physicians Study Group. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134 (2001), 136–151.
9. Anstrom, KJ, King, TE Jr, Lasky, JA, Martinez, FJ, for the Idiopathic Pulmonary Fibrosis Clinical Research Network Study Group. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366 (2012), 1968–1977.
10. Baumgartner, KB, Samet, JM, Stidley, CA, Colby, TV, Waldron, JA, Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155 (1997), 242–248.
11. Hubbard, R, Occupational dust exposure and the aetiology of cryptogenic fibrosing alveolitis. Eur Respir J Suppl 18 (2001), 119s–121s.
12. Taskar, VS, Coultas, DB, Is idiopathic pulmonary fibrosis an environmental disease?. Proc Am Thorac Soc 3 (2006), 293–298.
13. Armanios, MY, Chen, JJ, Cogan, JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356 (2007), 1317–1326.
14. Tsakiri, KD, Cronkhite, JT, Kuan, PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 104 (2007), 7552–7557.
15. Wang, Y, Kuan, PJ, Xing, C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 84 (2009), 52–59.
16. Nogee, LM, Dunbar, AE, Wert, SE, Askin, F, Hamvas, A, Whitsett, JA, A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 344 (2001), 573–579.
17. Stuart, BD, Choi, J, Zaidi, S, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet 47 (2015), 512–517.
18. Cogan, JD, Kropski, JA, Zhao, M, et al. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med 191 (2015), 646–655.
19. Kropski, JA, Lawson, WE, Young, LR, Blackwell, TS, Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis Model Mech 6 (2012), 9–17.
20. Fingerlin, TE, Murphy, E, Zhang, W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 45 (2013), 613–620.
21. Noth, I, Zhang, Y, Ma, SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 1 (2013), 309–317.
22. Evans, CM, Fingerlin, TE, Schwarz, MI, et al. Idiopathic pulmonary fibrosis: a genetic disease that involves mucociliary dysfunction of the peripheral airways. Physiol Rev 96 (2016), 1567–1591.
23. Seibold, MA, Wise, AL, Speer, MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364 (2011), 1503–1512.
24. Hunninghake, GM, Hatabu, H, Okajima, Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 368 (2013), 2192–2200.
25. Peljto, AL, Selman, M, Kim, DS, et al. The MUC5B promoter polymorphism is associated with IPF in a Mexican cohort but is rare among Asian ancestries. Chest 147 (2015), 460–464.
26. Stock, CJ, Sato, H, Fonseca, C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68 (2013), 436–441.
27. Zhang, Y, Noth, I, Garcia, JGN, Kaminski, N, A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 364 (2011), 1576–1577.
28. Roy, MG, Livraghi-Butrico, A, Fletcher, AA, et al. Muc5b is required for airway defence. Nature 505 (2015), 412–416.
29. Molyneaux, PL, Cox, MJ, Willis-Owen, SAG, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 190 (2014), 906–913.
30. Nakano, Y, Yang, IV, Walts, A, et al. MUC5B promoter variant rs35705950 affects MUC5B expression in the distal airways in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 193 (2016), 464–466.
31. Peljto, AL, Zhang, Y, Fingerlin, TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309 (2013), 2232–2239.
32. Desai, TJ, Brownfield, DG, Krasnow, MA, Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 507 (2014), 190–194.
33. Rock, JR, Barkauskas, CE, Cronce, MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 108 (2011), E1475–E1483.
34. Naikawadi, RP, Disayabutr, S, Mallavia, B, et al. Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis. JCI Insight, 1, 2016, e86704.
35. Alder, JK, Chen, JJ, Lancaster, L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 105 (2008), 13051–13056.
36. Kropski, JA, Pritchett, JM, Zoz, DF, et al. Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med 191 (2015), 417–426.
37. Liang, J, Zhang, Y, Xie, T, et al. Hyaluronan and TLR4 promote surfactant-protein-C- positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. Nat Med 22 (2016), 1285–1293.
38. Königshoff, M, Kramer, M, Balsara, N, et al. WNT1-inducible signaling protein–1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 119 (2009), 772–787.
39. Stewart, GA, Hoyne, GF, Ahmad, SA, et al. Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. J Pathol 199 (2003), 488–495.
40. Horowitz, JC, Thannickal, VJ, Epithelial-mesenchymal interactions in pulmonary fibrosis. Semin Respir Crit Care Med 27 (2006), 600–612.
41. Hung, C, Linn, G, Chow, Y-H, et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 188 (2013), 820–830.
42. Liu, F, Mih, JD, Shea, BS, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 190 (2010), 693–706.
43. Booth, AJ, Hadley, R, Cornett, AM, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med 186 (2012), 866–876.
44. Parker, MW, Rossi, D, Peterson, M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 124 (2014), 1622–1635.
45. Tschumperlin, DJ, Matrix, mesenchyme, and mechanotransduction. Ann Am Thorac Soc 12 (2015), S24–S29.
46. Chen, H, Qu, J, Huang, X, et al. Mechanosensing by the α6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis. Nat Commun 7 (2016), 1–12.
47. Huang, X, Yang, N, Fiore, VF, et al. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 47 (2012), 340–348.
48. Wipff, PJ, Rifkin, DB, Meister, JJ, Hinz, B, Myofibroblast contraction activates latent TGF- 1 from the extracellular matrix. J Cell Biol 179 (2007), 1311–1323.
49. Zhou, Y, Huang, X, Hecker, L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 123 (2013), 1096–1108.
50. Chilosi, M, Poletti, V, Zamò, A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 162 (2003), 1495–1502.
51. Boers, JE, Ambergen, AW, Thunnissen, FB, Number and proliferation of basal and parabasal cells in normal human airway epithelium. Am J Respir Crit Care Med 157 (1998), 2000–2006.
52. Hong, KU, Reynolds, SD, Watkins, S, Fuchs, E, Stripp, BR, Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. Am J Pathol 164 (2004), 577–588.
53. Chilosi, M, Poletti, V, Murer, B, et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of ΔN-p63. Lab Invest 82 (2002), 1335–1345.
54. Korfei, M, Skwarna, S, Henneke, I, et al. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax 70 (2015), 1022–1032.
55. Yang, IV, Coldren, CD, Leach, SM, et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 68 (2013), 114–121.
56. King, T, Tooze, J, Schwarz, M, Brown, K, Cherniack, R, Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164 (2001), 1171–1181.
57. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161 (2000), 646–664.
58. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165 (2002), 277–304.
59. Hansell, DM, Bankier, AA, MacMahon, H, McLoud, TC, Müller, NL, Remy, J, Fleischner Society: glossary of terms for thoracic imaging. Radiology 246 (2008), 697–722.
60. Travis, WD, Costabel, U, Hansell, DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 (2013), 733–748.
61. Hunninghake, GW, Lynch, DA, Galvin, JR, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 124 (2003), 1215–1223.
62. Hutchinson, JP, Fogarty, AW, McKeever, TM, Hubbard, RB, In-hospital mortality following surgical lung biopsy for interstitial lung disease in the USA: 2000–2011. Am J Respir Crit Care Med 193 (2016), 1161–1167.
63. Fell, CD, Martinez, FJ, Liu, LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181 (2010), 832–837.
64. Brownell, R, Moua, T, Henry, TS, et al. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax, 2017, 10.1136/thoraxjnl-2016-209671 published online Jan 12.
65. Jones, MG, Fabre, A, Schneider, P, et al. Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight, 1, 2016, e86375.
66. Cool, CD, Groshong, SD, Rai, PR, Henson, PM, Stewart, JS, Brown, KK, Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 174 (2006), 654–658.
67. Flaherty, KR, King, TE Jr, Raghu, G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med 170 (2004), 904–910.
68. Ryerson, CJ, Urbania, TH, Richeldi, L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 42 (2013), 750–757.
69. Bois du, RM, Weycker, D, Albera, C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 459–466.
70. Ley, B, Ryerson, CJ, Vittinghoff, E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156 (2012), 684–691.
71. Wells, AU, Desai, SR, Rubens, MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167 (2003), 962–969.
72. Kropski, JA, Young, LR, Cogan, JD, et al. Genetic evaluation and testing of patients and families with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2016, 10.1164/rccm.201609-1820PP published online Oct 27.
73. Talbert, JL, Schwartz, DA, Steele, MP, Familial interstitial pneumonia (FIP). Clin Pulm Med 21 (2014), 120–127.
74. Holohan, B, Wright, WE, Shay, JW, Telomeropathies: an emerging spectrum disorder. J Cell Biol 205 (2014), 289–299.
75. Lamas, DJ, Kawut, SM, Bagiella, E, Philip, N, Arcasoy, SM, Lederer, DJ, Delayed access and survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 842–847.
76. Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192 (2015), e3–19.
77. Raghu, G, Behr, J, Stowasser, S, Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 46 (2015), 1113–1130.
78. Cottin, V, The impact of emphysema in pulmonary fibrosis. Eur Respir Rev 22 (2013), 153–157.
79. Lancaster, LH, Mason, WR, Parnell, JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136 (2009), 772–778.
80. Cottin, V, Le Pavec, J, Prevot, G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 35 (2010), 105–111.
81. Raghu, G, Behr, J, Brown, KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158 (2013), 641–649.
82. Malouf, MA, Hopkins, P, Snell, G, Glanville, A, An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 16 (2011), 776–783.
83. Noth, I, Anstrom, KJ, Calvert, SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186 (2012), 88–95.
84. King, TE Jr, Brown, KK, Raghu, G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 92–99.
85. Daniels, CE, Lasky, JA, Limper, AH, Mieras, K, Gabor, E, Schroeder, DR, Imatinib treatment for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181 (2010), 604–610.
86. Raghu, G, Million-Rousseau, R, Morganti, A, Perchenet, L, Behr, J, for the MUSIC study group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 42 (2013), 1622–1632.
87. Martinez, FJ, de Andrade, JA, Anstrom, KJ, King, TE Jr, Raghu, G, for the Idiopathic Pulmonary Fibrosis Clinical Research Network Study Group. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2093–2101.
88. Zisman, DA, Schwarz, M, Schwarz, M, Anstrom, KJ, Collard, HR, Flaherty, KR, Hunninghake, GW for the Idiopathic Pulmonary Fibrosis Clinical Research Network, Study Group. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363 (2010), 620–628.
89. Richeldi, L, Bois du, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.
90. King, TE Jr, Bradford, WZ, Castro-Bernardini, S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092.
91. Noble, PW, Albera, C, Bradford, WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
92. Hilberg, F, Roth, GJ, Krssak, M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68 (2008), 4774–4782.
93. Chaudhary, NI, Roth, GJ, Hilberg, F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29 (2007), 976–985.
94. Richeldi, L, Costabel, U, Selman, M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365 (2011), 1079–1087.
95. Costabel, U, Inoue, Y, Richeldi, L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 193 (2016), 178–185.
96. Lee, BS, Margolin, SB, Nowak, RA, Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 83 (1998), 219–223.
97. Schaefer, CJ, Ruhrmund, DW, Pan, L, Seiwert, SD, Kossen, K, Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20 (2011), 85–97.
98. Taniguchi, H, Ebina, M, Kondoh, Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35 (2010), 821–829.
99. Noble, PW, Bradford, WZ, Costabel, U, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 47 (2016), 27–30.
100. European Medicines Agency. Pirfenidone. Annex I: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf, 2015 (accessed Oct 1, 2016).
101. European Medicines Agency. Nintedanib. Annex I: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002569/WC500179970.pdf, 2015 (accessed Oct 1, 2016).
102. Schmidinger, M, Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl 11 (2013), 172–191.
103. Kistler, KD, Nalysnyk, L, Rotella, P, Esser, D, Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med, 14, 2014, 788.
104. Collard, HR, Moore, BB, Flaherty, KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 (2007), 636–643.
105. Collard, HR, Ryerson, CJ, Corte, TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 194 (2016), 265–275.
106. Parambil, J, Myers, J, Ryu, JH, Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 128 (2015), 3310–3315.
107. Song, JW, Hong, SB, Lim, CM, Koh, Y, Kim, DS, Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37 (2011), 356–363.
108. Bajwah, S, Higginson, IJ, Ross, JR, et al. Specialist palliative care is more than drugs: a retrospective study of ILD patients. Lung 190 (2012), 215–220.
109. Bajwah, S, Ross, JR, Peacock, JL, et al. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax 68 (2013), 867–879.
110. Hope-Gill, BDM, Hilldrup, S, Davies, C, Newton, RP, Harrison, NK, A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168 (2003), 995–1002.
111. Ryerson, CJ, Cayou, C, Topp, F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med 108 (2014), 203–210.
112. Dowman, L, Hill, CJ, Holland, AE, Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev, 10, 2014 CD006322.
113. Swigris, JJ, Fairclough, DL, Morrison, M, et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care 56 (2011), 783–789.
114. Raghu, G, Wells, AU, Nicholson, AG, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 195 (2017), 78–85.
115. Walsh, SLF, Wells, AU, Desai, SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 4 (2016), 557–565.
116. Walsh, SLF, Calandriello, L, Sverzellati, N, Wells, AU, Hansell, DM, for the UIP Observer Consort Study Group. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 71 (2016), 45–51.
117. Tomassetti, S, Wells, AU, Costabel, U, et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 193 (2016), 745–752.
118. Johannson, KA, Marcoux, VS, Ronksley, PE, Ryerson, CJ, Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease: a systematic review and meta-analysis. Ann Am Thorac Soc 13 (2016), 1828–1838.
119. Karimi-Shah, BA, Chowdhury, BA, Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib. N Engl J Med 372 (2015), 1189–1191.
120. Albera, C, Fagan, EA, Glassberg, MK, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 48 (2016), 843–851.
121. Nathan, SD, Albera, C, Bradford, WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 71 (2016), 429–435.
122. National Institute for Health and Care Excellence. Technology appraisal guidance TA282. Pirfenidone for treating idioapthic pulmonary fibrosis. https://www.nice.org.uk/guidance/ta282, 2013 (accessed Oct 1, 2016).
123. Oldham, JM, Ma, SF, Martinez, FJ, et al. TOLLIP, MUC5B and the response to N-acetylcysteine among Individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 192 (2015), 1475–1482.
124. Tobin, RW, Pope, CE, Pellegrini, CA, Emond, MJ, Sillery, J, Raghu, G, Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158 (1998), 1804–1808.
125. Lee, JS, Collard, HR, Raghu, G, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis?. Am J Med 123 (2010), 304–311.
126. Lee, JS, Ryu, JH, Elicker, BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 1390–1394.
127. Lee, JS, Collard, HR, Anstrom, KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1 (2013), 369–376.
128. Kreuter, M, Wuyts, W, Renzoni, E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 4 (2016), 381–389.
129. Raghu, G, Morrow, E, Collins, BF, et al. Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. Eur Respir J 48 (2016), 826–832.
130. Han, MK, Zhou, Y, Murray, S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2 (2014), 548–646.
131. Shulgina, LL, Cahn, APA, Chilvers, ERE, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 68 (2013), 155–162.
132. Varney, VA, Parnell, HM, Salisbury, DT, Ratnatheepan, S, Tayar, RB, A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther 21 (2008), 178–187.
133. Jenkins, RG, Simpson, JK, Saini, G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 3 (2015), 462–472.
134. Rosas, IO, Richards, TJ, Konishi, K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med, 5, 2008, e93.
135. O'Dwyer, DN, Armstrong, ME, Trujillo, G, et al. The toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 188 (2013), 1442–1450.
136. Herazo-Maya, JD, Noth, I, Duncan, SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med, 5, 2013, 205ra136.
137. Prasse, A, Probst, C, Bargagli, E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179 (2009), 717–723.
138. Behr, J, Bendstrup, E, Crestani, B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 4 (2016), 445–453.
139. Ogura, A, Taniguchi, H, Azuma, A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 45 (2015), 1382–1392.
140. Rockey, DC, Bell, PD, Hill, JA, Fibrosis—a common pathway to organ injury and failure. N Engl J Med 372 (2015), 1138–1149.